Volasertib (trihydrochloride)
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models[1][2].
Product Specifications
CAS Number
946161-17-7
Product Name Alternative
BI 6727 (trihydrochloride)
UNSPSC
12352005
Target
Apoptosis; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/volasertib-trihydrochloride.html
Purity
99.12
Solubility
H2O : ≥ 100 mg/mL
Smiles
O=C(C1=CC=C(C(OC)=C1)NC2=NC=C(N(C3=O)C)C(N([C@@H]3CC)C(C)C)=N2)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6.[H]Cl.[H]Cl.[H]Cl
Molecular Formula
C34H53Cl3N8O3
Molecular Weight
728.20
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PLK1; PLK2; PLK3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Bcl-2 (BCL2/782), CF405S conjugate, 0.1mg/mL
